Mflusiva News

The U.S. Food and Drug Administration (FDA) has approved mFlusiva, the first mRNA-based influenza vaccine developed by Moderna, for individuals aged 50 and olde

The FDA has approved Moderna's mFlusiva, a new flu vaccine for adults aged 50 or older, which utilizes the same mRNA technology that was crucial in developing t

The U.S. FDA has approved Moderna's first mRNA flu shot, mFlusiva, for adults aged 50 to 64 with traditional approval and for those 65 and older with accelerate